TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07419295: A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 590 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$4,264,260

Rescue Site Savings

+$2,820,972

Unlock Full NCT07419295 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07419295 Rescue Dossier →